Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 321 SUMMER STREET, SUITE 400 BOSTON MA 02210 |
Tel: | N/A |
Website: | https://www.inozyme.com |
IR: | See website |
Key People | ||
Douglas A. Treco Chairman of the Board, Chief Executive Officer | Sanjay S. Subramanian Chief Financial Officer | Matthew Winton Chief Operations Officer |
Business Overview |
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis. |
Financial Overview |
For the fiscal year ended 31 December 2023, Inozyme Pharma Inc revenues was not reported. Net loss increased 6% to $71.2M. Higher net loss reflects Research and development increase of 15% to $54.8M (expense), Interest expense increase from $262K to $3.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.78 to -$1.37. |
Employees: | 59 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $127.98M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$74.81M as of Dec 31, 2023 |
Net annual income (TTM): | -$71.17M as of Dec 31, 2023 |
Free cash flow (TTM): | -$70.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 61,771,977 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |